| abstract |
Disclosed is the use of a combretastatin or combretastatin phosphate prodrug in the manufacture of a medicament for the treatment of ocular disease in a subject in need. The combretastatin phosphate prodrug is formulated for non-systemic administration and comprises an amount of combretastatin phosphate prodrug in the range of from 0.1 mg/ml to 100 mg/ml. Non-systemic administration to the eye of the subject is via intravitreal injection, sub-conjunctival injection, peri-ocular injection, sub-Tenon's injection, via ophthalmic drops, via ophthalmic gel, via ophthalmic ointment, via iontophoresis and via ocular implant and/or ocular insert and wherein the ocular disease is a non-malignant vascular proliferative disorder. |